Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation

Drug Discovery Today

Volumn 14, Issue 21-22, 2009, Pages 1067-1074

  Bansal, Tripta ^a   Akhtar, Naseem ^a   Jaggi, Manu ^b   Khar, Roop K ^a   Talegaonkar, Sushama ^a  

^a HAMDARD UNIVERSITY   (India)

^b DABUR RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GLYCOPROTEIN P; LIPOSOME; NANOCAPSULE; NANOPARTICLE; NIFEDIPINE; PACLITAXEL; POLOXAMER; POLYMER; QUINIDINE; SURFACTANT; TAMOXIFEN; VERAPAMIL; VINBLASTINE;

CANCER RESISTANCE; CRITICAL MICELLE CONCENTRATION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TRANSPORT; EMULSION; ENCAPSULATION; HUMAN; MULTIDRUG RESISTANCE; NANOPHARMACEUTICS; NONHUMAN; REVIEW; TUMOR; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; EXCIPIENTS; HUMANS; P-GLYCOPROTEIN;

EID: 70350393672     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.07.010     Document Type: Review

References (66)

1. Bansal T., et al. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J. Pharm. Pharm. Sci. 12 (2009) 46-78
2. Buggins T.R., et al. The effects of pharmaceutical excipients on drug disposition. Adv. Drug Deliv. Rev. 59 (2007) 1482-1503
3. Kim C.K., and Lim S.J. Recent progress in drug delivery systems for anticancer agents. Arch. Pharm. Res. 25 (2002) 229-239
4. Dharmala K., et al. Development of chitosan-SLN microparticles for chemotherapy: in vitro approach through efflux-transporter modulation. J. Control Rel. 131 (2008) 190-197
5. Wong H.L., et al. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci. 93 (2004) 1993-2008
6. Wong H.L., et al. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59 (2007) 148-157, 491-504
7. Krishna R., and Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11 (2000) 265-283
8. Dabholkar R.D., et al. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int. J. Pharm. 315 (2006) 148-157
9. Kobayashi T., et al. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int. J. Pharm. 329 (2007) 94-102
10. Haley B., and Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol. 26 (2008) 57-64
11. Lo Y.L. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J. Control Rel. 90 (2003) 37-48
12. Batrakova E.V., and Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control Rel. 130 (2008) 98-106
13. Sachs-Barrable K., et al. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J. Pharm. Pharm. Sci. 10 (2007) 319-331
14. Cornaire G., et al. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int. J. Pharm. 278 (2004) 119-131
15. Riehm H., and Biedler J.L. Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin. Cancer Res. 32 (1972) 1195-1200
16. Woodcock D.M., et al. Reversal of multidrug resistance by surfactants. Br. J. Cancer 66 (1992) 62-68
17. Rege B.D., et al. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 16 (2002) 237-246
18. Varma M.V., and Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci. 25 (2005) 445-453
19. Wempe M.F., et al. Inhibiting efflux with novel non-ionic surfactants: rational design based on vitamin E TPGS. Int. J. Pharm. 370 (2009) 93-102
20. Zhu S., et al. Effects of polyoxyethylene (40) stearate on the activity of P-glycoprotein and cytochrome P450. Eur. J. Pharm. Sci. (2009)
21. Collnot E.M., et al. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J. Control Rel. 111 (2006) 35-40
22. Ho P.Y., et al. Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. Int. J. Pharm. 359 (2008) 174-181
23. Batrakova E.V., et al. Effects of Pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm. Res. 15 (1998) 850-855
24. Foger F., et al. In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials 27 (2006) 4250-4255
25. Bernkop-Schnürch A., and Grabovac V. Polymeric efflux pump inhibitors in oral drug delivery. Am. J. Drug Deliv. 4 (2006) 263-272
26. Carreno-Gomez, B. and Duncan, R. (2002) Compositions with enhanced oral bioavailability (vol. USP 20030211072)
27. Werle M. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm. Res. 25 (2008) 500-511
28. Shen Q., et al. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int. J. Pharm. 313 (2006) 49-56
29. D'Emanuele A., et al. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J. Control Rel. 95 (2004) 447-453
30. Werle M., and Hoffer M. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J. Control Rel. 111 (2006) 41-46
31. Bromberg L. Polymeric micelles in oral chemotherapy. J. Control Rel. 128 (2008) 99-112
32. Elamanchili P., et al. Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function. J. Pharm. Sci. 98 (2009) 945-958
33. Nassar T., et al. Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. J. Control Rel. 133 (2009) 77-84
34. Chavanpatil M.D., et al. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int. J. Pharm. 320 (2006) 150-156
35. Chavanpatil M.D., et al. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol. Pharm. 4 (2007) 730-738
36. Vinogradov S.V., et al. Poly(ethylene glycol)-polyethyleneimine NanoGel™ particles: novel drug delivery systems for antisense oligonucleotides. Colloids Surf. B: Biointerf. 16 (1999) 291-304
37. Alakhov V., et al. Block copolymer-based formulation of doxorubicin from cell screen to clinical trials. Colloids Surf. B: Biointerf. 16 (1999) 113-134
38. Danson S., et al. Phase I dose escalation and pharmacokinetic study of Pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer 90 (2004) 2085-2091
39. St'astny M., et al. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier. Eur. J. Cancer 35 (1999) 459-466
40. Bromberg L., and Alakhov V. Effects of polyether-modified poly(acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J. Control Rel. 88 (2003) 11-22
41. Liu Z., et al. Triton-X-100-modified polymer and microspheres for reversal of multidrug resistance. J. Pharm. Pharmacol. 53 (2001) 779-787
42. Lamprecht A., and Benoit J.P. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J. Control Rel. 112 (2006) 208-213
43. Koziara J.M., et al. In vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J. Control Rel. 112 (2006) 312-319
44. Yang S., et al. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm. Res. 21 (2004) 261-270
45. Nornoo A.O., et al. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. Eur. J. Pharm. Biopharm. (2008)
46. Lo Y., et al. Effect of PSC 833 liposomes and Intralipid on the transport of epirubicin in Caco-2 cells and rat intestines. J. Control Rel. 76 (2001) 1-10
47. Dadashzadeh S., et al. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Int. J. Pharm. 353 (2008) 251-259
48. Mamot C., et al. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist. Updat. 6 (2003) 271-279
49. Wong H.L., et al. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J. Control Rel. 116 (2006) 275-284
50. Foger F., et al. In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein. Biomaterials 27 (2006) 5855-5860
51. Hugger E.D., et al. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J. Pharm. Sci. 91 (2002) 1991-2002
52. Lin Y., et al. Effects of Labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine123, a P-glycoprotein substrate, in rats. Biol. Pharm. Bull. 30 (2007) 1301-1307
53. Shono Y., et al. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J. Pharm. Sci. 93 (2004) 877-885
54. Zordan-Nudo T., et al. Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res. 53 (1993) 5994-6000
55. Vinogradov S.V., et al. Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J. Control Rel. 107 (2005) 143-157
56. Zhang Z., and Feng S.S. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27 (2006) 4025-4033
57. Patil Y., et al. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control Rel. 136 (2009) 21-29
58. Zhang Z., and Feng S.S. Self-assembled nanoparticles of poly(lactide)-vitamin E TPGS copolymers for oral chemotherapy. Int. J. Pharm. 324 (2006) 191-198
59. Iffert T., et al. Modulation of daunorubicin toxicity by liposomal encapsulation and use of specific inhibitors in vitro. Toxicology 144 (2000) 189-195
60. Immordino M.L., et al. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Control Rel. 91 (2003) 417-429
61. Elkharraz K., et al. Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization. Int. J. Pharm. 314 (2006) 127-136
62. St'astny M., et al. HPMA-hydrogels containing cytostatic drugs. Kinetics of the drug release and in vivo efficacy. J. Control Rel. 81 (2002) 101-111
63. Tanino T., et al. Paclitaxel-2'-Ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity. Pharm. Res. 24 (2007) 555-565
64. Guillemard V., and Uri Saragovi H. Prodrug chemotherapeutics bypass P-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene 23 (2004) 3613-3621
65. Choi J.S., and Jo B.W. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int. J. Pharm. 280 (2004) 221-227
66. Ho E.A., et al. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. J. Control Rel. 117 (2007) 20-27